2. Academic Validation
  3. A7RC peptide modified paclitaxel liposomes dually target breast cancer

A7RC peptide modified paclitaxel liposomes dually target breast cancer

  • Biomater Sci. 2015 Dec;3(12):1545-54. doi: 10.1039/c5bm00161g.
Jingyan Cao 1,  Ran Wang,  Ning Gao,  Minghui Li,  Xuyu Tian,  Weili Yang,  Ying Ruan,  Chunlan Zhou,  Guangtian Wang,  Xiaoying Liu,  Shukun Tang,  Yan Yu,  Ying Liu,  Guangyu Sun,  Haisheng Peng,  Qun Wang
Affiliations

Affiliation

  • 1 Department of Medical Oncology, The Tumor Hospital of Harbin Medical University, 150 Hapin Road, Harbin, 150086, China.
PMID: 26291480 DOI: 10.1039/c5bm00161g
Abstract

A7R peptide (ATWLPPR), a ligand of the NRP-1 receptor, regulates the intracellular signal transduction related to tumor vascularization and tumor growth. Here, we designed A7R-cysteine peptide (A7RC) surface modified paclitaxel liposomes (A7RC-LIPs) to achieve targeting delivery and inhibition of tumor growth and angiogenesis simultaneously. The cytotoxicity, inhibiting angiogenesis, and internalization of various liposomes by cells were assessed in vitro to confirm the influence of the peptide modification. The accumulations of A7RC-LIPs in various xenografts in mice were tracked to further identify the function of the peptide on the liposomes' surface. The results confirmed that A7RC peptides could enhance the uptake of vesicles by MDA-MB-231 cells, leading to stronger cytotoxicity in vitro and higher accumulation of vesicles in MDA-MB-231 xenografts in vivo. In addition, A7RC peptides enhanced the inhibitory effects of LIPs on the HUVEC tubular formation on Matrigel. The A7RC-LIPs may be promising drug carriers for Anticancer therapy.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P11286
    肿瘤靶向肽
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z